Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03333343
Title Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals

lung non-small cell carcinoma


LXH 254 + Nazartinib

Nazartinib + Trametinib

Gefitinib + Nazartinib

Nazartinib + Ribociclib

Capmatinib + Nazartinib

Age Groups: senior | adult
Covered Countries ITA | DEU | CAN

No variant requirements are available.